Neuropace Historical Balance Sheet
| NPCE Stock | USD 10.66 0.96 9.90% |
Trend analysis of Neuropace balance sheet accounts such as Total Current Liabilities of 19.4 M provides information on Neuropace's total assets, liabilities, and equity, which is the actual value of Neuropace to its prevalent stockholders. By breaking down trends over time using Neuropace balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Neuropace latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neuropace is a good buy for the upcoming year.
Neuropace Inventory |
|
Neuropace |
About Neuropace Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Neuropace at a specified time, usually calculated after every quarter, six months, or one year. Neuropace Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neuropace and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neuropace currently owns. An asset can also be divided into two categories, current and non-current.
Neuropace Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Neuropace assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neuropace books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Neuropace balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neuropace are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most accounts from Neuropace's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neuropace current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.At present, Neuropace's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 1.1 M, whereas Short and Long Term Debt Total is forecasted to decline to about 67.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 49.8M | 69.8M | 72.4M | 67.7M | Total Assets | 133.6M | 114.1M | 107.7M | 95.1M |
Neuropace balance sheet Correlations
Click cells to compare fundamentals
Neuropace Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Revenue Per Share 2.697 | Quarterly Revenue Growth 0.282 | Return On Assets (0.15) | Return On Equity (2.15) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.